FIELD: medicine.
SUBSTANCE: antibody-drug conjugate loaded with binary toxins. By contacting MMAF with another drug fragment in a row at the cysteine binding sites on the antibody, both can have a synergistic effect, thereby effectively improving the tumor cell destruction effect.
EFFECT: provision of a novel solution for the development of high performance and low toxicity ADCs.
14 cl, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OLIGOPEPTIDE LINKER INTERMEDIATE AND METHOD FOR PRODUCTION THEREOF | 2019 |
|
RU2775973C1 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA | 2019 |
|
RU2750817C1 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| MONOMETHYLVALINE COMPOUNDS CAPABLE OF FORMING CONJUGATES WITH LIGANDS | 2004 |
|
RU2448117C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2787617C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
